vs
ANI PHARMACEUTICALS INC（ANIP）とGULFPORT ENERGY CORP（GPOR）の財務データ比較。上の社名をクリックして会社を切り替えられます
GULFPORT ENERGY CORPの直近四半期売上が大きい（$398.2M vs $247.1M、ANI PHARMACEUTICALS INCの約1.6倍）。GULFPORT ENERGY CORPの純利益率が高く（33.3% vs 11.1%、差は22.1%）。GULFPORT ENERGY CORPの前年同期比売上増加率が高い（66.0% vs 29.6%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 18.6%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ガルフポート・エナジー・コープは米国に本拠を置く独立系石油・天然ガス探査・生産企業です。主にオハイオ州ユーティカシェール層やオクラホマ州SCOOP鉱区で事業を展開し、天然ガス、原油、天然ガス液を生産して北米の産業、公益事業、商業部門向け市場に供給しています。
ANIP vs GPOR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $398.2M |
| 純利益 | $27.5M | $132.4M |
| 粗利率 | — | 76.6% |
| 営業利益率 | 14.1% | 44.9% |
| 純利益率 | 11.1% | 33.3% |
| 売上前年比 | 29.6% | 66.0% |
| 純利益前年比 | 367.5% | 148.5% |
| EPS（希薄化後） | $1.14 | $7.98 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $398.2M | ||
| Q3 25 | $227.8M | $379.7M | ||
| Q2 25 | $211.4M | $447.6M | ||
| Q1 25 | $197.1M | $197.0M | ||
| Q4 24 | $190.6M | $239.9M | ||
| Q3 24 | $148.3M | $253.9M | ||
| Q2 24 | $138.0M | $181.1M | ||
| Q1 24 | $137.4M | $283.2M |
| Q4 25 | $27.5M | $132.4M | ||
| Q3 25 | $26.6M | $111.4M | ||
| Q2 25 | $8.5M | $184.5M | ||
| Q1 25 | $15.7M | $-464.0K | ||
| Q4 24 | $-10.3M | $-273.2M | ||
| Q3 24 | $-24.2M | $-14.0M | ||
| Q2 24 | $-2.3M | $-26.2M | ||
| Q1 24 | $18.2M | $52.0M |
| Q4 25 | — | 76.6% | ||
| Q3 25 | — | 74.6% | ||
| Q2 25 | — | 80.7% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 63.2% | ||
| Q3 24 | — | 64.6% | ||
| Q2 24 | — | 52.2% | ||
| Q1 24 | — | 69.4% |
| Q4 25 | 14.1% | 44.9% | ||
| Q3 25 | 15.9% | 41.9% | ||
| Q2 25 | 6.6% | 56.0% | ||
| Q1 25 | 13.3% | 6.1% | ||
| Q4 24 | -2.3% | -131.3% | ||
| Q3 24 | -13.8% | 5.7% | ||
| Q2 24 | 3.7% | -10.0% | ||
| Q1 24 | 14.8% | 28.9% |
| Q4 25 | 11.1% | 33.3% | ||
| Q3 25 | 11.7% | 29.3% | ||
| Q2 25 | 4.0% | 41.2% | ||
| Q1 25 | 8.0% | -0.2% | ||
| Q4 24 | -5.4% | -113.9% | ||
| Q3 24 | -16.3% | -5.5% | ||
| Q2 24 | -1.7% | -14.5% | ||
| Q1 24 | 13.2% | 18.4% |
| Q4 25 | $1.14 | $7.98 | ||
| Q3 25 | $1.13 | $4.45 | ||
| Q2 25 | $0.36 | $9.12 | ||
| Q1 25 | $0.69 | $-0.07 | ||
| Q4 24 | $-0.45 | $-14.72 | ||
| Q3 24 | $-1.27 | $-0.83 | ||
| Q2 24 | $-0.14 | $-1.51 | ||
| Q1 24 | $0.82 | $2.34 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $1.8M |
| 総負債低いほど良い | — | $788.2M |
| 株主資本純資産 | $540.7M | $1.8B |
| 総資産 | $1.4B | $3.0B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.43× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $1.8M | ||
| Q3 25 | $262.6M | $3.4M | ||
| Q2 25 | $217.8M | $3.8M | ||
| Q1 25 | $149.8M | $5.3M | ||
| Q4 24 | $144.9M | $1.5M | ||
| Q3 24 | $145.0M | $3.2M | ||
| Q2 24 | $240.1M | $1.2M | ||
| Q1 24 | $228.6M | $8.2M |
| Q4 25 | — | $788.2M | ||
| Q3 25 | — | $691.7M | ||
| Q2 25 | — | $695.2M | ||
| Q1 25 | — | $700.4M | ||
| Q4 24 | — | $702.9M | ||
| Q3 24 | — | $694.4M | ||
| Q2 24 | — | $679.5M | ||
| Q1 24 | — | $636.4M |
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.8B | ||
| Q1 25 | $418.6M | $1.7B | ||
| Q4 24 | $403.7M | $1.7B | ||
| Q3 24 | $405.9M | $2.1B | ||
| Q2 24 | $455.8M | $2.1B | ||
| Q1 24 | $452.0M | $2.2B |
| Q4 25 | $1.4B | $3.0B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.3B | $3.0B | ||
| Q1 25 | $1.3B | $2.9B | ||
| Q4 24 | $1.3B | $2.9B | ||
| Q3 24 | $1.3B | $3.2B | ||
| Q2 24 | $920.8M | $3.2B | ||
| Q1 24 | $914.5M | $3.3B |
| Q4 25 | — | 0.43× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.39× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | 0.32× | ||
| Q1 24 | — | 0.29× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $185.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.40× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $185.4M | ||
| Q3 25 | $44.1M | $209.1M | ||
| Q2 25 | $75.8M | $231.4M | ||
| Q1 25 | $35.0M | $177.3M | ||
| Q4 24 | $15.9M | $148.8M | ||
| Q3 24 | $12.5M | $189.7M | ||
| Q2 24 | $17.4M | $123.5M | ||
| Q1 24 | $18.3M | $188.0M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 1.40× | ||
| Q3 25 | 1.66× | 1.88× | ||
| Q2 25 | 8.87× | 1.25× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 3.61× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GPOR
| Natural Gas Production | $296.9M | 75% |
| Other | $42.7M | 11% |
| Naturalgasliquidsales | $35.2M | 9% |
| Oil And Condensate | $23.4M | 6% |
